Aspirin for primary prevention of heart attack gains AHA support, more data needed.
This article was originally published in The Tan Sheet
Executive Summary
ASPIRIN FOR HEART ATTACK PRIMARY PREVENTION "MAY BE WARRANTED" in at-risk individuals, the American Heart Association recommends in a scientific statement published in the Oct. 21 issue of the journal Circulation. AHA notes, however, that any policy recommendation on primary prevention of cardiovascular disease would be "premature" until more evidence from random primary prevention trials is collected. Entitled "Aspirin as a Therapeutic Agent in Cardiovascular Disease," the statement directed at health care professionals was prepared by Charles Hennekens, MD, Brigham & Women's Hospital, Boston, et al.